Treatment with Vyvgart (efgartigimod alfa-fcab) helped reduce the impact of generalized myasthenia gravis (gMG) on activities of daily…
Margarida Maia, PhD
Science Writer
Margarida Maia, PhD, is a science and medical writer with a background in biochemistry and biomedical sciences. She studied in Portugal and Belgium and has been working in science communication for several years. She has been writing at Bionews since 2021. Her work focuses on explaining new research and medical developments on rare diseases in a clear and accessible way.
Education
- PhD in Biomedical Sciences, VIB & KU Leuven, Belgium
- Degree in Biochemistry, University of Porto, Portugal
Certifications
- Google Project Management: Professional Certificate
Published Works
- Valdez, Y, Maia, M, Conway EM. CD248: Reviewing its role in health and disease. Curr Drug Targets. 2012;13:432–439.
- Maia, M et al. CD248 facilitates tumor growth via its cytoplasmic domain. BMC Cancer. 2011;11:162.
- Antunes, R, Brandão, C, Maia, M, Arosa, FA. Red blood cells release factors with growth and survival bioactivities for normal and leukemic T cells. Immunol Cell Biol. 2011;89:111–121.
- Maia, M et al. CD248 and its cytoplasmic domain: A therapeutic target for arthritis. Arthritis Rheum. 2010;62:.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Margarida Maia, PhD
Tapping into PD-1/PD-L1 immune checkpoint proteins — which serve as a kind of natural off switch for an overactive immune…
A case report from Germany showed that two women with severe, treatment-resistant myasthenia gravis (MG) responded well to blinatumomab,…
Azathioprine did not outperform standard treatment in helping adults with myasthenia gravis (MG) live longer, and while older age…
Povetacicept, a treatment for autoimmune diseases in the pipeline of Vertex Pharmaceuticals, reduced disease activity in a study with…
Vor Bio has signed an exclusive license agreement to develop and market Remegen’s telitacicept — a B-cell-targeting candidate…
Plasma exchange — a procedure that clears antibodies, such as those that cause myasthenia gravis (MG), from the blood…
Dosing has started in the first group of healthy adults participating in a clinical study of S-1117, a candidate treatment…
Tacrolimus, an immunosuppressant sometimes used off-label to treat adults with myasthenia gravis (MG), eased symptoms of the disease in…
People with more severe myasthenia gravis (MG) have a greater likelihood of experiencing episodes of exacerbation, when symptoms worsen…